

Irene Hernández-Lozano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4167639/publications.pdf>

Version: 2024-02-01

15
papers

127
citations

1478280

6
h-index

1281743

11
g-index

15
all docs

15
docs citations

15
times ranked

114
citing authors

#	ARTICLE	IF	CITATIONS
1	PET imaging to assess the impact of P-glycoprotein on pulmonary drug delivery in rats. <i>Journal of Controlled Release</i> , 2022, 342, 44-52.	4.8	11
2	Pharmacokinetic Imaging Using ^{99m} Tc-Mebrofenin to Untangle the Pattern of Hepatocyte Transporter Disruptions Induced by Endotoxemia in Rats. <i>Pharmaceutics</i> , 2022, 15, 392.	1.7	2
3	Use of PET Imaging to Assess the Efficacy of Thiethylperazine to Stimulate Cerebral MRP1 Transport Activity in Wild-Type and APP/PS1-21 Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6514.	1.8	2
4	Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats. <i>Journal of Controlled Release</i> , 2022, 349, 109-117.	4.8	5
5	Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [¹¹ C]erlotinib. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 1634-1646.	2.4	17
6	Influence of Cation Transporters (OCTs and MATEs) on the Renal and Hepatobiliary Disposition of [¹¹ C]Metoclopramide in Mice. <i>Pharmaceutical Research</i> , 2021, 38, 127-140.	1.7	1
7	Repurposing ^{99m} Tc-Mebrofenin as a Probe for Molecular Imaging of Hepatocyte Transporters. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1043-1047.	2.8	4
8	Imaging-Based Characterization of a Slco2b1(-/-) Mouse Model Using [¹¹ C]Erlotinib and [^{99m} Tc]Mebrofenin as Probe Substrates. <i>Pharmaceutics</i> , 2021, 13, 918.	2.0	2
9	Assessing the Functional Redundancy between P-gp and BCRP in Controlling the Brain Distribution and Biliary Excretion of Dual Substrates with PET Imaging in Mice. <i>Pharmaceutics</i> , 2021, 13, 1286.	2.0	7
10	Influence of ABC transporters on the excretion of ciprofloxacin assessed with PET imaging in mice. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 163, 105854.	1.9	7
11	Measurement of Hepatic ABCB1 and ABCG2 Transport Activity with [¹¹ C]Tariquidar and PET in Humans and Mice. <i>Molecular Pharmaceutics</i> , 2020, 17, 316-326.	2.3	15
12	Validation of Pharmacological Protocols for Targeted Inhibition of Canalicular MRP2 Activity in Hepatocytes Using [^{99m} Tc]mebrofenin Imaging in Rats. <i>Pharmaceutics</i> , 2020, 12, 486.	2.0	7
13	Use of imaging to assess the activity of hepatic transporters. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 149-164.	1.5	17
14	Assessing the Activity of Multidrug Resistance-Associated Protein 1 at the Lung Epithelial Barrier. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1650-1657.	2.8	16
15	Towards Improved Pharmacokinetic Models for the Analysis of Transporter-Mediated Hepatic Disposition of Drug Molecules with Positron Emission Tomography. <i>AAPS Journal</i> , 2019, 21, 61.	2.2	14